Abstract
T-cell prolymphocytic leukemia (T-PLL) is a rare, aggressive neoplasm derived from post-thymic T-cells. Patients are typically middle aged with a slight male predominance who present with a high white blood cell count, hepatosplenomegaly, lymphadenopathy, and other symptoms typically associated with leukemia. Although cutaneous involvement has been reported in up to 30% of cases of T-PLL, to our knowledge, none have presented with a presentation resembling livedoid vasculopathy. In the correct clinical context, an underlying hematolymphoid neoplasm should be included in the differential diagnosis of a patient presenting with livedoid vasculopathy.
Keywords:
T-cell prolymphocytic leukemia; alemtuzumab; livedoid vasculopathy.
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
MeSH terms
-
Aged
-
Alemtuzumab / therapeutic use
-
Antineoplastic Agents, Alkylating / administration & dosage
-
Antineoplastic Agents, Alkylating / therapeutic use
-
Antineoplastic Agents, Immunological / therapeutic use
-
Bendamustine Hydrochloride / administration & dosage
-
Bendamustine Hydrochloride / therapeutic use
-
Biopsy / methods
-
Diagnosis, Differential
-
Disease Progression
-
Exanthema / etiology
-
Exanthema / pathology
-
Extremities / pathology
-
Fatal Outcome
-
Humans
-
Hyperpigmentation / diagnosis
-
Hyperpigmentation / etiology*
-
Immunohistochemistry / methods
-
Leukemia, Prolymphocytic, T-Cell / diagnosis*
-
Leukemia, Prolymphocytic, T-Cell / drug therapy
-
Leukemia, Prolymphocytic, T-Cell / metabolism*
-
Male
-
Skin Neoplasms / pathology*
-
Torso / pathology
-
Vascular Diseases / diagnosis*
-
Vascular Diseases / pathology
Substances
-
Antineoplastic Agents, Alkylating
-
Antineoplastic Agents, Immunological
-
Alemtuzumab
-
Bendamustine Hydrochloride